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What was known before: 1 
Homonymous visual field defects can have a severe impact on functional ability and quality of life 2 
following stroke. Patients with visual field defects report increased risk of falling, impaired ability to 3 
read, altered activities of daily living, loss of confidence and institutionalization. 4 
 5 
 6 
What this study adds: 7 
Composite scores differed systematically for the NEI VFQ-25 (Neuro 10) versus NEI VFQ-25 at all 8 
time points. The questions contained in the Neuro 10 may not be appropriate to capture aspects of 9 
vision that are deficient in patients with hemianopia. For subscale scores, descriptive statistics 10 
suggest clinically relevant improvement in distance activities and vision-specific dependency 11 
subscales for NEI VFQ-25 scores in the visual search treatment arm. 12 
  13 
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Abstract 97 
Background: We conduct supplementary analyses of the NEI VFQ-25 data to evaluate where changes 98 
occurred within subscales of the NEI VFQ-25 leading to change in the composite scores between the 99 
three treatment arms, and evaluate the NEI VFQ-25 with and without the Neuro 10 supplement.  100 
Methods: A prospective, multicentre, parallel, single-blind, three-arm RCT of fourteen UK acute 101 
stroke units was conducted. Stroke survivors with homonymous hemianopia were recruited. 102 
Interventions included: Fresnel prisms for minimum 2 hours, 5 days/week over 6-weeks (Arm a), 103 
Visual search training for minimum 30 minutes, 5 days/week over 6-weeks (Arm b) and standard 104 
care-information only (Arm c). Primary and secondary outcomes (including NEI VFQ-25 data) were 105 
measured at baseline, 6, 12 and 26 weeks after randomisation.  106 
Results: Eighty seven patients were recruited (69% male; mean age (SD) equal to 69 (12) years). At 107 
26 weeks, outcomes for 24, 24 and 22 patients, respectively, were compared to baseline. NEI VFQ-25 108 
(with and without Neuro 10) responses improved from baseline to 26 weeks with visual search 109 
training compared to Fresnel prisms and standard care. In subscale analysis, the most impacted 110 
across all treatment arms was ‘driving’ whilst the least impacted were ‘colour vision’ and ‘ocular 111 
pain’.  112 
Conclusions: Composite scores differed systematically for the NEI VFQ-25 (Neuro 10) versus NEI 113 
VFQ-25 at all time points. For subscale scores, descriptive statistics suggest clinically relevant 114 
improvement in distance activities and vision-specific dependency subscales for NEI VFQ-25 scores in 115 
the visual search treatment arm.  116 
 117 
Trial Registration: Current Controlled Trials ISRCTN05956042. 118 
 119 
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Standard care; Stroke; Visual search training; Visual Function Questionnaire-25; Quality of life 121 
 122 
Background 123 
Homonymous hemianopia results in loss of one-half of the visual field in both eyes [1, 2]. The mean 124 
prevalence of visual field loss following stroke has been reported as 31%, although there are large 125 
variations in figures reported by individual studies [3].  126 
Homonymous visual field defects can have a severe impact on functional ability and quality of life 127 
following stroke [4, 5]. Patients with visual field defects report increased risk of falling, impaired 128 
ability to read, altered activities of daily living, loss of confidence and institutionalization [4, 6, 7]. 129 
There may also be an impact on the patient’s ability to participate in rehabilitation as a result of 130 
visual field loss which may ultimately affect prognosis and long-term recovery [7]. There is an 131 
increased risk of accidents or injuries with visual field loss, which subsequently has cost implications 132 
to the NHS and society [8].  133 
Two clinically used interventions to improve vision in hemianopia are visual search compensatory 134 
training and provision of monocular prisms [9]. These interventions for homonymous hemianopia 135 
were evaluated by a Cochrane systematic review and limited evidence was found in favour of visual 136 
search training [10]. Aimola et al., subsequently reported a trial of visual search training for 137 
homonymous hemianopia and provided evidence of improved quality of life in the intervention 138 
group [11]. Insufficient evidence was found by the Cochrane review relating to prisms as an 139 
intervention for hemianopia [10].  140 
The National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) was designed to measure 141 
vision-related quality of life[12].  This outcome tool has been used in several studies to measure 142 
quality of life in stroke survivors with visual field loss [13-18].  These studies have all reported 143 
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subscale scores separately in addition to the composite score having used the NEI VFQ-25 without 144 
the additional Neuro-10 supplement (Neuro 10) [19].  This raises the question of whether the Neuro 145 
10 supplement is appropriate for assessing outcome in populations experiencing visual field loss due 146 
to neurological aetiology. Neuro 10 was developed with the aim of adapting the NEI VFQ to be 147 
better targeted to a neurological population [19].. It is important to select an outcome measure 148 
instrument that it is both valid and acceptable for the population of interest, which does not include 149 
irrelevant questions and considers the burden of completion [20-22].  150 
The Visual Impairment after Stroke: Intervention Or Not (VISION) pilot trial sought to evaluate visual 151 
search training versus prism therapy versus standard care (control) [23]. In particular, the primary 152 
objective of VISION was to estimate the parameters required for the calculation of sample size for a 153 
definitive trial. Secondary measures included Rivermead Mobility Index, NEI VFQ-25 (Neuro 10), 154 
Nottingham Extended Activities of Daily Living, EuroQol, Short Form-12 questionnaires and Radner 155 
reading ability. We previously reported that visual function using the NEI VFQ 25, including the 156 
Neuro 10 supplement, improved at 26 weeks in the visual search training arm when compared to 157 
the Fresnel prisms and standard care arms, with no evidence of differences across arms with other 158 
secondary outcomes [24]. At that stage, a detailed analysis of the subscales of the NEI VFQ-25 159 
(Neuro 10) was not conducted. However the data collected from participants within this trial provide 160 
a valuable opportunity to explore the subscale analysis and additional information, if any, gained 161 
from administering the Neuro 10 supplement in addition to the standard NEI VFQ-25. 162 
 163 
The aims of this analysis were to evaluate where changes occurred within subscales of the NEI VFQ-164 
25 leading to change in the composite score between the three treatment arms and to evaluate the 165 
NEI VFQ-25 with and without the Neuro 10 supplement.   166 
 167 
Methods 168 
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Detailed trial methodology has been published elsewhere [23, 24]. Briefly, the VISION trial was a 169 
randomised controlled, multicentre pilot trial with NHS research ethical approval (10/H1003/119). 170 
Participants were recruited from stroke units based in 14 NHS Trusts and randomised to one of three 171 
possible treatment arms: prism therapy, visual search training or standard NHS care.  172 
Participants were eligible for inclusion if they met the criteria: 173 
a. 18 years of age or older; 174 
b. Best corrected visual acuity of 0.5 or better in each eye at distance; 175 
c. Stable homonymous hemianopia (partial or complete) induced by recent stroke, defined following 176 
WHO guidelines, present over 2 weeks (to exclude rapid recovery cases) but less than 26 weeks prior 177 
to randomisation;  178 
d. Refractive error within ±5Dioptres; 179 
e. Willing and able to give consent for the study; 180 
f. Prior to stroke able to read and understand English. 181 
Participants were not eligible for inclusion if they were: 182 
a. unable to consent due to severe cognitive impairment; 183 
b. assessed to have ocular motility impairment and/or visual inattention in addition to the visual 184 
field impairment; or 185 
c. had pre-existent visual field impairment due to previous stroke. 186 
Participants eligible for inclusion, and providing consent, attended a baseline assessment, which 187 
included assessment and documentation of patient demographics, visual signs and symptoms, visual 188 
acuity measures, any additional ocular problems, comorbidity, severity of stroke and level of 189 
disability.   190 
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This study focuses on the data analysis from the NEI VFQ-25 and supplementary Neuro 10. The NEI-191 
VFQ 25 is composed of 12 subscales, 11 of which are vision-related: general health (1 item), general 192 
vision (1 item), near vision activities (3 items), distance vision activities (3 items), social functioning 193 
(2 items), role limitation (2 items), dependency (3 items), mental health (4 items), driving (3 items), 194 
peripheral vision (1 item), colour vision (1 item) and ocular pain (2 items) [12]. The instrument 195 
provides an overall composite score by averaging the 11 vision-related subscales. Both composite 196 
and subscale scores range from 0 (“worst functioning”) to 100 (“best functioning”) [25]. The Neuro 197 
10 is composed of 10 items; tired eyes, bright sunlight, parking a car, using a computer, two eyes 198 
seeing differently, eye/lid appearance unusual, blurred vision, trouble focusing on moving objects, 199 
binocular double vision and ptosis. While guidelines for the Neuro 10 demonstrate how to merge 200 
supplement items with the NEI VFQ-25 to compute an overall score, they do not map onto 201 
subscales. The additional Neuro 10 items were included in the existing subscales of the NEI VFQ-25, 202 
by consensus using an expert panel, comprising four expert neuro-orthoptists (from the British and 203 
Irish Orthoptic Society Stroke and Neuro-rehabilitation Clinical Advisory Group). The expert panel 204 
achieved immediate consensus on the classification of seven of the ten items of the Neuro 10 205 
supplement into the sub scales of the NEI VFQ-25 (Table 1). The remaining three items were 206 
discussed by these experts and consensus agreed during a second discussion. 207 
 208 
A full statistical analysis plan, which rigorously describes the statistical analysis and methods used, 209 
was developed and approved prior to the conduction of this analysis. Descriptive analysis was 210 
performed with the use of SAS software, version 9.3 (SAS Institute) and according to the intention-211 
to-treat principle. Scores were calculated on patients with data at both time points only, no 212 
imputation methods were used. As the VISION trial was not powered to identify differences, and this 213 
analysis is on data collected as a secondary outcome, results should be interpreted with caution and 214 
are exploratory only. No formal statistical testing was undertaken.   215 
 216 
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The analysis of the NEI VFQ-25 (Neuro 10) followed the same principles as in the main analysis of the 217 
VISION trial (12, 13). To check the robustness resulting from mapping the additional ten items to the 218 
standard NEI VFQ-25, analyses were also performed separately on NEI VFQ-25 data as a sensitivity 219 
measure. A clinically significant change was defined as 10 points difference (26, 27). Data from 220 
baseline, 26 weeks (final follow up), and the difference between these two time points are 221 
presented descriptively overall, and split by treatment arm and subscale. Count data was 222 
summarised by counts and percentages. Continuous outcomes are summarised using means and 223 
standard deviations since no significant deviations from normality were observed.  224 
 225 
Results 226 
Participants 227 
Between 17 May 2011 and 9 September 2013, 87 participants were recruited from 1171 stroke 228 
survivors assessed for eligibility. The reasons for not being eligible and for refusing to consent were 229 
recorded and have been published [28]. The 87 participants were randomised, 27 to Fresnel prisms, 230 
30 to visual search training and 30 to standard care. Two participants (2.3%) withdrew from data 231 
analysis and follow-up; nine (10.3%) from follow-up only and five (5.7%) were lost to follow-up, of 232 
which four were from the standard arm. At 26 weeks follow-up, there were 24 (88.9%) in Fresnel 233 
prisms, 25 (83.3%) in visual search training and 22 (73.3%) in standard care. NEI VFQ-25 (Neuro 10) 234 
data was available at baseline for 83 participants in total; 25 participants in Fresnel prisms, 30 in 235 
visual search training and 28 in standard care. At 26 weeks follow-up, NEI VFQ-25 (Neuro 10) data 236 
was available for 68 participants in total; 24 participants in Fresnel prisms, 25 in visual search 237 
training and 19 in standard care. 238 
 239 
Participant demographic and clinical characteristics of all randomised participants at baseline are 240 
outlined fully in the main results paper [24]. There were no notable differences at baseline between 241 
the three arms for participant demographics. The population consisted primarily of white (97.6%) 242 
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males (69.4%) with an average age of 69 years, randomized, on average, at 11 weeks post-stroke 243 
stroke. The stroke location was mostly classified as unilateral (43.5% left; 54.1% right), with 47 244 
(55.3%) complete and 38 (44.7%) partial homonymous hemianopia.  245 
Composite scores 246 
The mean (SD) composite score of the NEI VFQ-25 with Neuro 10 from all participants was 63.2 247 
(18.3) at baseline and 65.9 (20.5) at 26 weeks follow-up [24]. The mean (SD) composite score of the 248 
NEI VFQ-25 without Neuro 10 from all participants was 54.6 (17.7) at baseline and 56.3 (19.6) at 26 249 
weeks. The mean (SD) difference across the three treatment arms between baseline and 26 week 250 
follow-up with Neuro 10 was 2.6 (15.2) and without Neuro 10 was 1.8 (14.0). The composite scores 251 
across the three treatment arms for baseline and 26 weeks follow-up with and without the Neuro 10 252 
supplement are outlined in Table 2.  253 
Notable differences were present at baseline between the three arms for NEI VFQ-25 data with 254 
higher scores for the Fresnel prism arm versus standard care and visual search strategy arms. The 255 
average composite without Neuro 10 score (SD) for the Fresnel prism arm at baseline was the 256 
highest of the three treatment arms at 59.5 (15.5), with the visual search strategy arm being the 257 
lowest at 51.7 (18.8) and standard care being 52.4 (18.3). The average composite with the Neuro 10 258 
were consistently higher across the three treatment arms with Fresnel prims arm at 68.5 (16.2), 259 
visual search strategy at 59.5 (19.0) and standard care being 61.8 (SD 19.2).  260 
 261 
The remainder of the analysis refers to the NEI VFQ-25 without the Neuro 10 supplement. The only 262 
treatment arm to show improvement in the average composite score (SD) was the visual search 263 
strategy arm with a mean difference of 7.2 (15.5) at 26 weeks follow-up when compared to baseline, 264 
resulting in a composite score of 58.9 (19.2) at 26 weeks. The Fresnel prism and standard care arms 265 
dropped slightly by -0.9 (13.1) and -2.1 (11.1) respectively.   266 
 267 
Subscale scores 268 
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The subscale scores are outlined in Table 3. The most impacted subscale across all treatment arms 269 
was driving, with the average score (SD) being 3.5 (15.1) from a maximum score of 14 within this 270 
subscale. The least impacted subscale across all three treatment arms was colour vision at 89.8 271 
(17.9), followed by ocular pain at 84.9 (22.1), however the score for the latter dropped in the 272 
standard care arm at 26 weeks follow-up by 6.6 (23.8).  273 
 274 
The change in scores between baseline and 26 week follow-up is displayed in Figure 1. Overall, the 275 
scores across ten of the twelve subscales improved between baseline and 26 weeks follow-up. The 276 
remaining two subscales (general health and colour vision) scores deteriorated. None of the changes 277 
for the overall cohort exceeded the clinically significant figure of 10. The Fresnel prism arm improved 278 
in four subscales (general vision, ocular pain, near activities and peripheral vision) and deteriorated 279 
in seven (general health, distance activities, vision-specific social functioning, vision-specific mental 280 
health, vision specific role difficulties, vision-specific dependency, colour vision) subscales. None of 281 
the changes for the Fresnel prism arm exceeded the clinically significant figure of 10.  The visual 282 
search strategy arm improved in ten subscales (general vision, ocular pain, near activities, distance 283 
activities, vision-specific social functioning, vision-specific mental health, vision-specific role 284 
difficulties, vision-specific dependency, driving and peripheral vision) and deteriorated in two 285 
subscales (general health and colour vision). The change seen in the distance activities, vision-286 
specific role difficulties and vision-specific dependency subscales exceeded the clinically significant 287 
threshold of 10 in the visual search strategy arm; the change in the other subscales did exceed this 288 
threshold. The standard care arm improved in two subscales (near activities and vision-specific role 289 
difficulties) and deteriorated in seven (general health, general vision, ocular pain, distance activities, 290 
vision-specific mental health, vision-specific dependency and colour vision) subscales. The change 291 
seen in the vision-specific role difficulties subscale exceeded the clinically significant threshold of 10 292 
in the standard care arm; the change in the other subscales did exceed this threshold. 293 
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Across the three treatment arms there were four instances of an improvement greater than the 294 
clinically relevant 10 points. Three were in the visual search strategy arm and one in the standard 295 
care arm, across three subscales; distance activities, vision-specific role difficulties and vision-specific 296 
dependency. The largest improvement of 15.2 (31.4) was seen in the vision-specific dependency sub-297 
scale for the visual search strategy arm. The visual search strategy arm also showed a large 298 
improvement of 10.5 (27.8) in the distance activities subscale. Both the visual search strategy and 299 
standard care arms had improvements of 13.6 (25.5) and -10.4 (23.6), respectively in the vision-300 
specific role difficulties subscale.  301 
 302 
 303 
Discussion 304 
In this exploratory analysis of the NEI VFQ-25 (with/without the Neuro 10 supplement) composite 305 
and subscale scores, we found 1) at all time points, the composite scores with the Neuro 10 306 
supplement were consistently higher than scores for the NEI VFQ-25 without Nero 10 supplement, 307 
and, 2) the subscale changes in each of the treatment arms demonstrated that the visual search 308 
intervention had a clinically relevant improvement on distance vision and dependency subscales, but 309 
not for other subscales.  310 
 311 
The VISION trial asked participants to complete the NEI VFQ-25 with the Neuro 10 supplement; 312 
these figures are published alongside other outcome measures elsewhere [24]. The mean composite 313 
score when the Neuro 10 supplement was included was systematically higher (63.8 and 65.9) at both 314 
baseline and 26 week time points respectively, suggesting consistency in the way it captures aspects 315 
of quality of life. A number of the questions included in the Neuro 10 supplement are focused 316 
towards ocular motility and central vision problems. The Neuro 10 supplement is recommended for 317 
use alongside the NEI VFQ-25 questionnaire in neurological populations. However, the 318 
supplementary questions may be suitable for certain populations such as multiple sclerosis where 319 
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symptoms/signs can also include double vision and eye appearance (reflecting the multiple sclerosis 320 
population with which the Neuro 10 supplement was developed [19]). Items such as ‘my eye or 321 
eyelid appearance is unusual’ are not associated with post-stroke hemianopia and therefore 322 
responders within this cohort were likely to answer this item ‘definitely false’ [19]. Scores obtained 323 
using the NEI VFQ-25 (Neuro 10) will therefore be higher than scores obtained using the NEI VFQ-25 324 
alone. In addition to the items not being relevant to visual field loss, the inclusion of these additional 325 
ten questions for this population potentially results in a higher task burden for the participant and 326 
may potentially mask the true impact of the visual field loss. This questions the utility of adding the 327 
Neuro 10 supplement to assess vision-related quality of life at specific time points, as well as change 328 
in vision-related quality of life over time, when evaluating visual field loss. A future recommendation 329 
would be to exclude the Neuro 10 supplement when assessing vision-related quality of life in a 330 
population with stroke related visual field loss and using the NEI VFQ-25 only. 331 
 332 
Several studies have previously used the NEI VFQ-25 (without Neuro 10 supplement) in stroke 333 
populations with homonymous hemianopia. The composite score calculated in this study of 54.6 (SD 334 
17.7) is lower than that reported by other studies. Gall and colleagues reported a composite score of 335 
64.93 (SD 16.01) and 63.98 (SD 16.89) in two studies indicating slightly better quality of life than in 336 
the VISION trial. However both studies by Gall et al. did have higher proportions (58.2% and 58.4%) 337 
of partial hemianopia/quadrantanopia, i.e. less visual field loss [13, 15]. George and colleagues 338 
reported a composite score of 63.6 (SD 18.3) similar to those reported by Gall et al., however their 339 
study had a higher proportion (62.5%) of complete hemianopia [16]. One study by Papageorgiou and 340 
colleagues reported the highest composite score of 77.1 which may be the result of less than 33% of 341 
participants having a complete homonymous hemianopia [18].   342 
 343 
Gall et al. and Papageorgiou et al. both reported the NEI VFQ-25 subscale scores [15, 18]. Gall et al. 344 
reported nine of the twelve subscales with very similar scores to the findings of this trial [13]. The 345 
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exceptions to this were near activities at 65.25 (SD 22.69) (18.9 points better than the mean scores 346 
in this study); vision-specific social functioning at 74.65 (SD 23.33) (23.7 points better); and driving at 347 
27.35 (SD 33.89) (23.9 points better) [13]. Papageorgiou et al. only reported four of the twelve 348 
subscales with similar scores to the findings of this trial. The remaining eight subscales were 349 
reported to have consistently better scores, ranging from 14.8 to 31.6 points higher than those 350 
found by the current trial [18].  351 
 352 
As a cohort, participants were found to improve in all subscales with the exceptions of general 353 
health and colour vision, between baseline and 26 weeks. Both of these exceptions were below 10 354 
points which is considered to represent clinical relevance [26, 27]. All subscales saw a minor amount 355 
of change between baseline and 26-week follow-up. When split by treatment arm some changes 356 
were found to have potential clinical relevance. The distance activities, vision-specific mental health 357 
and vision-specific dependency subscales all improved by between a mean of 9.6 to 15.2 in the visual 358 
search strategy arm. The same subscales had slight deterioration in mean score for the Fresnel prism 359 
and standard care arms. The vision-specific role difficulties subscale had a mean score improvement 360 
of clinical relevance in both the visual search and standard care arms, whereas the Fresnel prism arm 361 
had a slight deterioration in mean score.  The peripheral vision subscale showed an improvement in 362 
mean score for both the Fresnel prism and visual search arms, whereas the standard care mean 363 
score remained unchanged between baseline and 26-week follow up.  364 
 365 
This study is limited as represents a supplementary analysis of a pilot trial that was not powered to 366 
identify differences on the VFQ scale. Furthermore, notable differences for NEI VFQ-25 scores at 367 
baseline across arms were present (Fresnel prism arm higher than visual search strategy and 368 
standard care). However, results presented are consistent with a larger observational study 369 
indicating that these are representative of the wider population with post-stroke visual field loss 370 
[15]. In addition, unlike other studies, this data was collected as part of a randomised trial in a 371 
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controlled setting, and therefore adds to the evidence base within the literature and provides scope 372 
for further investigation [13, 15, 18]. As such, we would recommend an adequately powered trial is 373 
needed to formally compare the differences observed here and to balance for potential differences 374 
in scores across treatment arms at baseline and follow-up time points.  375 
 376 
Conclusion 377 
When using the NEI VFQ-25, improvement over time was noted for the visual search strategy arm 378 
specific to distance activities and vision-specific dependency subscales only. Scores differed overall 379 
for the NEI VFQ-25 (Neuro 10) versus the NEI VFQ-25. The questions contained in the Neuro 10 may 380 
not be appropriate to capture aspects of vision that are deficient in patients with hemianopia. We 381 
conclude that the NEI VFQ-25 without the Neuro 10 supplement may be more suited for use with 382 
populations with stroke-related visual field loss to capture relevant changes of impact on quality of 383 
life. 384 
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Table 1: Classification of additional items of the NEI VFQ-25 (10) supplement on to subscales of the NEI VFQ-25 
Item Discussion 1 Discussion 2  Subscale agreed 
1. How much difficulty do you have performing tasks when your 
eyes are tired? 
Consensus not achieved 
3 general vision 
1 ocular pain 
Consensus achieved General vision 
2.  Because of your vision, how much difficulty do you have 
identifying objects or performing tasks in bright sunlight? 
Consensus achieved  General vision 
3.  Because of your vision, how much difficulty do you have parking 
a car? 
Consensus achieved  Driving 
4.  Because of your vision, how much difficulty do you have using a 
computer? 
Consensus achieved  Near activities 
5. I have a feeling that my two eyes see differently, even with 
correction (glasses or contact lenses) 
Consensus achieved  General vision 
6. I have a feeling that my eye or eyelid appearance is unusual 
Consensus not achieved 
2 vision specific social functioning 
2 general vision 
Consensus achieved Vision specific social 
functioning 
7. My vision is blurry, not clear, or “fuzzy” Consensus achieved  General vision 
8. I have trouble focusing on or following moving objects Consensus achieved  General vision 
9. I have double vision with both eyes open that is not present 
when either eye is covered 
Consensus achieved  General vision 
10. My eyelid(s) droop 
Consensus not achieved 
2 vision specific social functioning 
2 general vision 
Consensus achieved General vision 
 
 
 
Table 2: Composite score summary of visual function questionnaire (NEI VFQ-25) and (NEI VFQ-25 (Neuro 10)) 
 NEI VFQ-25  NEI VFQ-25 (10)  
 Treatment  Treatment  
 Fresnel 
prisms 
Visual 
search 
strategies 
Standard 
care 
Total Fresnel 
prisms 
Visual search 
strategies 
Standard 
care 
Total 
Patients Randomised 26 30 29 85 26 30 29 85
Baseline data 25 30 28 83 25 30 28 83
26 weeks data 24 25 19 68 24 25 19 68 
Data at both time points 23 25 19 67 23 25 19 67 
Baseline 
mean (sd) 
(min, max) 
 
59.5 (15.5) 
(16.0, 84.6) 
 
51.7 (18.8) 
(24.6, 82.2) 
 
52.4 (18.3) 
(24.4, 81.2) 
 
54.6 (17.7) 
(16.0, 84.6) 
 
68.5 (16.2) 
(19.8, 93.9) 
 
59.5 (19.0) 
(32.2, 92.9) 
 
61.8 (19.2) 
(35.0, 91.0) 
 
63.2 (18.3) 
(19.8, 93.9) 
26 week follow-up 
assessment 
mean (sd) 
(min, max) 
 
58.6 (17.9) 
(16.0, 88.1) 
58.9 (19.2) 
(18.8, 88.0) 
50.3 (21.9) 
(13.6, 83.2) 
56.3 (19.6) 
(13.6, 88.1) 
 
68.1 (18.8) 
(18.2, 96.5) 
68.4 (20.0) 
(25.5, 99.2) 
59.8 (22.7) 
(22.9, 95.2) 
65.9 (20.5) 
(18.2, 99.2) 
Difference at 26 weeks 
from baseline 
mean (sd) 
95% CI 
 
-0.9 (13.1) 
-6.6 to 4.7 
 
7.2 (15.5) 
0.8 to 13.6 
 
-2.1 (11.1)  
-7.4 to 3.3 
 
1.8 (14.0) 
-1.6 to 5.2 
 
-0.4 (13.7) 
-6.3 to 5.5 
 
8.9 (16.8) 
2.0 to 15.8 
 
-1.9 (12.7) 
-8.1 to 4.1 
 
2.6 (15.2) 
-1.1 to 6.4 
 
 
1 
 
Table 3: Subscale scores of visual function questionnaire (NEI VFQ-25)   
Clinically significant changes of >10 points difference are indicated by shading 
  Treatment  
  Fresnel Prisms Visual Search Strategies Standard Care All treatment arms 
 
 
  
 
Baseline 26 weeks 
 
Means 
difference 
 Baseline 26 weeks Means 
difference 
 Baseline 26 weeks Means 
difference 
 Baseline 26 weeks Means 
difference 
Subscale  n mean (SD) 
 
mean (SD) 
 
mean (SD)  
95% CI 
n mean (SD) 
 
mean (SD) 
 
mean (SD)  
95% CI 
n mean (SD) 
 
mean (SD) 
 
mean (SD)  
95% CI 
n mean (SD) 
 
mean (SD) 
 
mean (SD) 
95% CI 
Overall (Excluding 
general health) 23 59.5 (15.5) 58.6 (17.9) 
-0.9 (13.1) 
-6.6 to 4.7  25 51.7 (18.8) 58.9 (19.2) 
7.2 (15.5) 
0.8 to 13.6 19 52.4 (18.3)  50.3 (21.9) 
-2.1 (11.1)  
-7.4 to 3.3 67 54.6 (17.7) 56.3 (19.6) 
1.8 (14.0) 
-1.6 to 5.2 
General health 23 55.4 (22.6) 52.2 (21.2)  -3.3 (18.9)  -11.4 to 4.9 22 46.6 (24.8)  42.0 (22.3)  
-4.5 (27.4)  
-16.7 to 7.6 19 48.7 (25.6)  43.4 (23.3)  
-5.3 (22.9)  
-16.3 to 5.8 64 50.4 (24.2)  46.1 (22.4)  
-4.3 (23.0)  
-10.0 to 1.4 
General vision 23 59.1 (17.6)  61.7 (19.0)  2.6 (18.4) -5.3 to 10.6 23 53.9 (18.5)  60.9 (22.9)  
7.0 (19.6)  
-1.5 to 15.4 19 62.1 (17.5)  60.0 (16.3)  
-2.1 (11.3)  
-7.6 to 3.4 65 58.2 (17.9)  60.9 (19.5)  
2.8 (17.3)  
-1.5 to 7.1 
Ocular pain 23 86.4 (21.3)  89.1 (15.7)  2.7 (14.6)  -3.6 to 9.0 25 87.0 (20.2)  91.0 (11.7)  
4.0 (19.7)  
-4.1 to 12.1 19 80.3 (25.8)  73.7 (21.6)  
-6.6 (24.4)  
-18.4 to 5.2 67 84.9 (22.1)  85.4 (17.8)  
0.6 (19.9)  
-4.3 to 5.4 
Near activities 23 46.1 (20.2)  51.1 (17.5)  5.0 (17.2)  -2.5 to 12.4 24 47.1 (20.1)  50.3 (21.1)  
3.2 (18.2)  
-4.5 to 10.9 18 45.9 (19.2)  49.1 (25.1)  
3.1 (15.3)  
-4.5 to 10.7 65 46.4 (19.6)  50.3 (20.8)  
3.8 (16.9)  
-0.4 to 8.0 
Distance activities 23 75.4 (22.2)  72.1 (28.5)  -3.3 (24.0)  -13.7 to 7.1 25 65.0 (26.3)  75.5 (29.4)  
10.5 (27.8)  
-1.0 to 22.0 19 70.2 (23.9)  65.4 (25.6)  
-4.8 (15.0)  
-12.0 to 2.4 67 70.0 (24.3)  71.5 (28.0)  
1.4 (24.2)  
-4.5 to 7.3 
Vision 
specific 
Social 
functioning 
23 56.9 (10.6)  53.6 (16.6)  
-3.3 (14.2)    
-9.4 to 2.9 
22 47.9 (15.3)  52.7 (19.7)  
 
4.7 (17.8)     
-3.2 to 12.6 
19 47.4 (16.7)  47.4 (21.9) 0.0 (11.5)      
-5.5 to 5.5 
64 51.0 (14.7)  51.4 (19.2)  0.5 (15.0)     
-3.3 to 4.2 
 
Mental 
health 
23 57.1 (25.7)  54.9 (28.3)  -2.2 (21.2)    
-11.3 to 7.0 
25 48.1 (29.3)  57.7 (30.0)  
 
9.6 (21.7) 
0.6 to 18.5 
19 47.4 (28.4)  41.8 (30.1)  -5.6 (19.4)     
-15.0 to 3.8 
67 51.0 (27.8)  52.2 (29.8)  1.2 (21.6)     
-4.0 to 6.5 
 
Role 
difficulties 
22 59.7 (29.1)  53.4 (32.5)  -6.3 (34.4)    
-21.5 to 9.0 
23 48.9 (24.7)  62.5 (28.0)  13.6 (25.5) 
2.5 to 24.6 
18 39.6 (30.7)  50.0 (32.4)  10.4 (23.6)     
-1.3 to 22.1 
63 50.0 (28.8)  55.8 (30.9)  5.8 (29.4)     
-1.7 to 13.2 
 Dependency 23 71.7 (26.9)  64.5 (31.3)  
-7.2 (23.2)    
-17.3 to 2.8 
23 54.7 (36.0)  69.9 (31.3)  15.2 (31.4) 
1.6 to 28.8 
18 57.4 (32.8)  53.7 (34.3)  -3.7 (19.6)     
-13.5 to 6.1 
64 61.6 (32.5)  63.4 (32.3)  1.8 (27.2)     
-5.0 to 8.6 
Driving 14 9.4 (23.9)  9.2 (23.5)  -0.1 (0.6)      
-0.5 to 0.2 
15 0.0 (0.0)  4.6 (17.8)  4.6 (17.8)     
-5.2 to 14.4 
8 0.0 (0.0)  0.0 (0.0)  
 
0.0 (0.0)  
0.0 to 0.0 
37 3.5 (15.1)  5.3 (18.3)  
 
1.8 (11.3)     
-2.0 to 5.6  
Color vision 23 93.5 (17.2)  90.2 (22.3)  -3.3 (8.6)      
-7.0 to 0.5 
21 85.7 (18.7)  84.5 (29.0)  -1.2 (26.8)     
-13.4 to 11.0 
17 89.7 (17.8)  86.8 (25.2)  -2.9 (17.4)      
-11.9 to 6.0 
61 89.8 (17.9)  87.3 (25.3)  -2.5 (18.7)     
-7.2 to 2.3 
Peripheral vision 23 48.9 (21.9)  57.6 (23.2)  8.7 (26.8)      
-2.9 to 20.3 
21 47.6 (23.6)  52.4 (26.1)  4.8 (21.8)     
-5.2 to 14.7 
17 50.0 (26.5)  50.0 (26.5)  0.0 (25.0)      
-12.9 to 12.9 
61 48.8 (23.5)  53.7 (24.9)  4.9 (24.5)     
-1.4 to 11.2 
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Figure 1: NEI-VFQ excluding 10-item supplement difference in means between baseline and 26 weeks 
 
